Login to Your Account

In Wake of Prosensa Failure

Oh, Skip It? FDA View Changing; Sarepta’s DMD Efforts Hit Hard

By Randy Osborne
Staff Writer

Wednesday, November 13, 2013
The FDA altered its view of Sarepta Therapeutics Inc.’s data with exon-skipping therapy eteplirsen for Duchenne muscular dystrophy (DMD) after Prosensa Holding NV’s failure with exon-skipper drisapersen for the condition, but Sarepta CEO Chris Garabedian hopes the agency can still be brought around.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription